Rhumbline Advisers Geron Corp Transaction History

Rhumbline Advisers

  • $104 Billion
  • Q1 2025

A detailed history of Rhumbline Advisers transactions in Geron Corp stock. As of the latest transaction made, Rhumbline Advisers holds 839,456 shares of GERN stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
839,456
Previous 834,844 0.55%
Holding current value
$1.18 Million
Previous $2.96 Million 53.13%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 08, 2025
BUY
$1.59 - $3.6 $7,333 - $16,603
4,612 Added 0.55%
839,456 $1.39 Million
Q4 2024

Jan 30, 2025
BUY
$3.3 - $4.44 $39,831 - $53,590
12,070 Added 1.47%
834,844 $2.96 Million
Q3 2024

Nov 12, 2024
SELL
$4.17 - $4.99 $100,054 - $119,730
-23,994 Reduced 2.83%
822,774 $3.74 Million
Q2 2024

Aug 01, 2024
BUY
$3.1 - $5.09 $370,605 - $608,509
119,550 Added 16.44%
846,768 $3.59 Million
Q1 2024

May 09, 2024
BUY
$1.75 - $3.44 $31,631 - $62,178
18,075 Added 2.55%
727,218 $2.4 Million
Q4 2023

Feb 08, 2024
BUY
$1.74 - $2.31 $5,493 - $7,292
3,157 Added 0.45%
709,143 $1.5 Million
Q3 2023

Nov 09, 2023
SELL
$2.11 - $3.28 $4,027 - $6,261
-1,909 Reduced 0.27%
705,986 $1.5 Million
Q2 2023

Aug 08, 2023
BUY
$1.97 - $3.69 $266,458 - $499,102
135,258 Added 23.62%
707,895 $2.27 Million
Q1 2023

May 11, 2023
BUY
$2.14 - $3.4 $137,884 - $219,068
64,432 Added 12.68%
572,637 $1.24 Million
Q4 2022

Feb 14, 2023
BUY
$2.03 - $2.42 $17,453 - $20,807
8,598 Added 1.72%
508,205 $1.23 Million
Q3 2022

Nov 10, 2022
BUY
$1.67 - $2.94 $55,624 - $97,925
33,308 Added 7.14%
499,607 $1.17 Million
Q2 2022

Aug 11, 2022
BUY
$1.19 - $1.65 $136,212 - $188,865
114,464 Added 32.53%
466,299 $723,000
Q1 2022

May 12, 2022
SELL
$0.99 - $1.6 $36,647 - $59,228
-37,018 Reduced 9.52%
351,835 $478,000
Q4 2021

Feb 10, 2022
SELL
$1.22 - $1.72 $2,993 - $4,220
-2,454 Reduced 0.63%
388,853 $474,000
Q3 2021

Nov 12, 2021
BUY
$1.2 - $1.5 $10,808 - $13,510
9,007 Added 2.36%
391,307 $536,000
Q2 2021

Aug 05, 2021
SELL
$1.25 - $1.83 $55,833 - $81,740
-44,667 Reduced 10.46%
382,300 $539,000
Q1 2021

May 06, 2021
SELL
$1.52 - $2.1 $21,322 - $29,458
-14,028 Reduced 3.18%
426,967 $675,000
Q4 2020

Feb 10, 2021
BUY
$1.55 - $2.05 $118,365 - $156,548
76,365 Added 20.94%
440,995 $701,000
Q3 2020

Nov 12, 2020
BUY
$1.59 - $2.19 $81,605 - $112,399
51,324 Added 16.38%
364,630 $634,000
Q2 2020

Aug 13, 2020
BUY
$1.05 - $2.18 $14,765 - $30,655
14,062 Added 4.7%
313,306 $683,000
Q1 2020

May 06, 2020
BUY
$0.89 - $1.49 $18,249 - $30,552
20,505 Added 7.36%
299,244 $356,000
Q4 2019

Feb 05, 2020
BUY
$1.27 - $1.54 $5,237 - $6,350
4,124 Added 1.5%
278,739 $379,000
Q3 2019

Oct 23, 2019
BUY
$1.15 - $1.59 $27,464 - $37,972
23,882 Added 9.52%
274,615 $365,000
Q2 2019

Aug 14, 2019
BUY
$1.37 - $2.02 $51,351 - $75,715
37,483 Added 17.58%
250,733 $354,000
Q1 2019

May 01, 2019
SELL
$1.01 - $1.83 $4,723 - $8,558
-4,677 Reduced 2.15%
213,250 $354,000
Q4 2018

Jan 31, 2019
BUY
$0.98 - $1.85 $69,967 - $132,080
71,395 Added 48.72%
217,927 $218,000
Q3 2018

Nov 07, 2018
SELL
$1.76 - $6.38 $14,970 - $54,268
-8,506 Reduced 5.49%
146,532 $258,000
Q2 2018

Aug 06, 2018
BUY
$3.29 - $4.82 $57,887 - $84,807
17,595 Added 12.8%
155,038 $532,000
Q1 2018

May 02, 2018
SELL
$1.81 - $5.98 $8,326 - $27,508
-4,600 Reduced 3.24%
137,443 $584,000
Q4 2017

Feb 09, 2018
SELL
$1.8 - $2.32 $52,444 - $67,595
-29,136 Reduced 17.02%
142,043 $256,000
Q3 2017

Nov 06, 2017
BUY
$1.99 - $2.65 $340,646 - $453,624
171,179
171,179 $373,000

Others Institutions Holding GERN

# of Institutions
305
Shares Held
452M
Call Options Held
1.07M
Put Options Held
648K
View Full List

About GERON CORP

GERN Quotes by TradingView
  • Ticker GERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 377,819,008
  • Market Cap $533M
  • Description
  • Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...
More about GERN
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email